The American journal of the medical sciences
Real world evaluation of Evusheld in prevention of COVID-19 in immunocompromised patients: An observational cohort study.
Sarah Channey, Pramodini Kale-Pradhan, Mamta Sharma, Daniel Lebovic, Christopher Giuliano, Leonard Johnson, Ashish Bhargava
Published: 202510.1016/j.amjms.2025.11.007
Abstract
BACKGROUND: Evusheld®, a combination of monoclonal antibodies Tixagevimab and Cilgavimab, was developed for pre-exposure prophylaxis (PrEP) of coronavirus disease 2019 (COVID-19) in immunocompromised patients. However, real-world long-term data on it…
Preview only. Read the full abstract at the source